Oncology Learning Network

In an interview with Oncology Learning Network, Kevin Kalinsky, MD, MS, Herbert Irving Associate Professor of Medicine, NewYork-Presbyterian Hospital/Columbia University Medical Center, discussed why gene profiling plays such an important role in the management of patients with early-stage breast cancer.

Non-Chemotherapy Approach Induces High Rate of Undetectable MRD in CLL by HMP Global

KTE-X19 Shows Great Efficacy in Heavily Pretreated MCL by HMP Global

Joel Randolph Hecht, MD, David Geffen School of Medicine, University of California Los Angeles, shares findings from the SEQUOIA clinical trial of GEM-refractory pancreatic adenocarcinoma, an overview of recent studies and therapy options for metastatic pancreatic cancer, and what he believes may be the way forward to improve treatment outcomes in this patient population.

Matt Kalaycio, MD, Discusses the Historical Treatment of CML by HMP Global

Belantamab Mafodotin Demonstrates Promising Safety and Efficacy for MM by HMP Global

Front-Line Ibrutinib Plus Venetoclax Effective for CLL Irrespective of Patient Age by HMP Global

Marginal Zone Lymphoma: Biology and Treatment by HMP Global

Ruxolitinib-BET Inhibitor Combo Promising for Myelofibrosis by HMP Global

iFCG Regimen Effective for Young, Fit Patients With IGHV-Mutated CLL by HMP Global

In an interview with Oncology Learning Network, Michelle Melisko, MD, University of California San Francisco, and Melissa Bourestom, Dignitana, discussed the background, benefits, and future potential of the DigniCap Scalp Cooling System, which minimizes hair loss from certain chemotherapy treatments in patients with cancer.

Novel ABL1 Kinase Inhibitor Active in Heavily Pretreated CML by HMP Global

Acalabrutinib Alone or in Combination With Obinutuzumab Improves PFS in Treatment-Naïve CLL by HMP Global

Pacritinib Promising for Patients With Myelofibrosis and Severe Thrombocytopenia by HMP Global

Dr Pegram, Associate Director for Clinical Research, Stanford Comprehensive Cancer Institute, Palo Alto, California, spoke with Oncology Learning Network about the basis, findings, and clinical significance of the HER2CLIMB clinical trial examining the use of tucatinib therapy in patients with HER2-positive breast cancer.

Recapping a late-breaking abstract from ASCO 2019, Dr Abou-Alfa discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer. Since the recording of this podcast, olaparib has been approved by the FDA as maintenance therapy for gBRCA-mutated metastatic pancreatic cancer as of December 30, 2019.

Dawn Hershman, MD, MS, Professor of Medicine and Epidemiology at Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, discusses how the cost of breast cancer treatment is directly associated with rates of adherence, and explains why financial factors matter in treatment decisions.

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the benefits of clinical trial participation for patients with cancer.

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.

Dr Modi discusses the basis, clinical significance, and findings of the DESTINY-Breast04 trial of DS-8201a therapy for HER2-low breast cancer.

Novel BTK Inhibitor Shows Promising for Mantle Cell Lymphoma by HMP Global

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, spoke with Oncology Learning Network about data that was presented regarding the use of DS-8201a in the treatment of HER2-positive breast cancer.

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about advancements made in the treatment of patients with early stage, HER2-positive breast cancer.

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the HER2CLIMB study and the promising role of tucatinib in the treatment of metastatic, HER2-positive breast cancer.